{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:52:09Z","timestamp":1790275929176,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2008,8,20]],"date-time":"2008-08-20T00:00:00Z","timestamp":1219190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2008,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>Understanding the causes of failure in older patients with acute lymphocytic leukemia (ALL) may help improve treatment strategies for patients in this particular age group.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>The objectives of the current study were to define the causes of death in older patients (aged \u226560 years) with ALL during induction and consolidation\u2010maintenance with a dose\u2010intensive regimen of alternating 8 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper\u2010CVAD) with high doses of methotrexate and cytarabine followed by maintenance with 6\u2010mercaptopurine, vincristine, methotrexate, and prednisone and to compare their outcomes with the outcomes of older patients who received earlier, less intensive regimens and younger patients who received hyper\u2010CVAD. One hundred twenty\u2010two older patients who received hyper\u2010CVAD were compared with 34 older patients who received less intensive regimens and with 409 younger patients who received hyper\u2010CVAD.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>The complete response (CR) rates in older patients receiving hyper\u2010CVAD, older patients receiving other regimens, and younger patients receiving hyper\u2010CVAD were 84%, 59%, and 92%, respectively (<jats:italic>P<\/jats:italic> &lt; .001); and the respective induction mortality rates were 10%, 12%, and 2% (<jats:italic>P<\/jats:italic> not significant in older patients). The incidence of disease resistance during induction was 5%, 27%, and 2%, respectively (<jats:italic>P<\/jats:italic> &lt; .001). The majority of deaths were related to infections. Among patients who achieved a CR, death in CR was noted in 34%, 15%, and 7% of older patients receiving hyper\u2010CVAD, older patients receiving other regimens, and younger patients, respectively (<jats:italic>P<\/jats:italic> &lt; .001); and the respective rates of recurrence were 40%, 80%, and 48% (<jats:italic>P<\/jats:italic> = .004). The estimated 5\u2010year survival rates were 20%, 9%, and 48%, respectively (<jats:italic>P<\/jats:italic> &lt; .001).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>The results of the current study suggested that intensifying the chemotherapy in older patients with ALL reduced the incidence of leukemia resistance but increased the incidence of death in CR from myelosuppression\u2010associated infections. The overall benefit:risk ratio was favorable. Identifying novel, low\u2010intensity agents\/regimens for older patients with ALL may improve the results further. Cancer 2008. \u00a9 2008 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.23819","type":"journal-article","created":{"date-parts":[[2008,8,20]],"date-time":"2008-08-20T09:03:32Z","timestamp":1219223012000},"page":"2097-2101","source":"Crossref","is-referenced-by-count":117,"title":["Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia"],"prefix":"10.1002","volume":"113","author":[{"given":"Susan","family":"O'Brien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,10,3]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390907"},{"key":"e_1_2_5_3_2","first-page":"3310","article-title":"Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL\u2010BFM 90. German\u2010Austrian\u2010Swiss ALL\u2010BFM Study Group","volume":"95","author":"Schrappe M","year":"2000","journal-title":"Blood"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1211"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199806043382304"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20668"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11664"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70188-X"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70189-1"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70190-8"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70191-X"},{"key":"e_1_2_5_12_2","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/blood.V78.11.2814.2814","article-title":"Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow\u2010up report","volume":"78","author":"Linker CA","year":"1991","journal-title":"Blood"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70192-1"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04982.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400780"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.7.1813.1813"},{"key":"e_1_2_5_17_2","first-page":"1643","article-title":"Acute lymphoblastic leukemia in the elderly: results of 2 different treatment approaches in 49 patients during a 25\u2010year period","volume":"9","author":"Ferrari A","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2006.01.007"},{"key":"e_1_2_5_19_2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.1990.8.6.994","article-title":"Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard\u2010 and high\u2010risk acute lymphocytic leukemia","volume":"8","author":"Kantarjian HM","year":"1990","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.199"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0181"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-073528"},{"key":"e_1_2_5_23_2","first-page":"1126","article-title":"Minimal residual disease monitoring in adult T\u2010cell acute lymphoblastic leukemia: a molecular based approach using T\u2010cell receptor G and D gene rearrangements","volume":"87","author":"Gameiro P","year":"2002","journal-title":"Haematologica"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.4.1094"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2613"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2708"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-037093"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.23819","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.23819","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T15:57:15Z","timestamp":1760284635000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.23819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,3]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,10,15]]}},"alternative-id":["10.1002\/cncr.23819"],"URL":"https:\/\/doi.org\/10.1002\/cncr.23819","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,3]]}}}